Drug Shortage Report for REVATIO
Report ID | 181292 |
Drug Identification Number | 02341611 |
Brand name | REVATIO |
Common or Proper name | REVATIO |
Company Name | BGP PHARMA ULC |
Market Status | MARKETED |
Active Ingredient(s) | SILDENAFIL |
Strength(s) | 0.8MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 1 |
ATC code | C02KX |
ATC description | OTHER ANTIHYPERTENSIVES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2023-02-06 |
Estimated end date | 2023-03-28 |
Actual end date | 2023-02-24 |
Shortage status | Resolved |
Updated date | 2023-05-05 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2023-05-05 | French | Compare |
v4 | 2023-05-05 | English | Compare |
v3 | 2023-02-07 | English | Compare |
v2 | 2023-01-17 | French | Compare |
v1 | 2023-01-17 | English | Compare |
Showing 1 to 5 of 5